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Abstract
Background:  This study investigated the effects of hyperoxic treatment on growth,
angiogenesis, apoptosis, general morphology and gene expression in DMBA-induced rat
mammary tumors.
Methods: One group of animals was exposed to normobaric hyperoxia (1 bar, pO2 = 1.0 bar)
and another group was exposed to hyperbaric hyperoxia (1.5 bar, pO2 = 1.5 bar). A third group
was treated with the commonly used chemotherapeutic drug 5- Fluorouracil (5-FU), whereas
animals housed under normal atmosphere (1 bar, pO2 = 0.2 bar) served as controls. All
treatments were performed on day 1, 4, 7 and 10 for 90 min. Tumor growth was calculated from
caliper measurements. Biological effects of the treatment, was determined by assessment of
vascular morphology (immunostaining for von Willebrandt factor) and apoptosis (TUNEL
staining). Detailed gene expression profiles were obtained and verified by quantitative rtPCR.
Results:  Tumor growth was significantly reduced (~57–66 %) after hyperoxic treatment
compared to control and even more than 5-FU (~36 %). Light microscopic observations of the
tumor tissue showed large empty spaces within the tissue after hyperoxic treatment, probably
due to loss of glands as indicated by a strong down-regulation of glandular secretory proteins. A
significant reduction in mean vascular density (30–50%) was found after hyperoxic treatment.
Furthermore, increased apoptosis (18–21%) was found after hyperoxic treatment.
Conclusion: Thus, by increasing the pO2 in mammary tumor tissue using normobaric and
moderate hyperbaric oxygen therapy, a significant retardation in tumor growth is achieved, by
loss of glands, reduction in vascular density and enhanced cell death. Hyperbaric oxygen should
therefore be further evaluated as a tumor treatment.
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Background
Growth of solid tumors depends on adequate supply of
oxygen and nutrients. There are, however, marked differ-
ences in the vascular network in the different regions of
the tumor. In the centre, there is typically a hypoxic milieu
due to structural and functional vessel disturbances (per-
fusion- and diffusion-limited O2 delivery), while in the
periphery there is generally a denser vascular network
with subsequent improved blood flow. While normal tis-
sue can compensate for such an O2 deficiency by raising
the blood flow, large tumor areas cannot adequately
counteract the restriction in O2  supply and therefore
develop hypoxia. Thus, the HbO2 saturation is signifi-
cantly lower in tumors than in normal surrounding tissue,
with a gradual reciprocal decrease as the tumor increases
in size [1,2].
It is now widely accepted that hypoxia promotes tumor
growth, angiogenesis and reduce the effect of chemo- and
radiation- therapy [3-6]. We might therefore expect that
an increase in the oxygen-content in tumor tissue might
have the opposite effect.
Hyperbaric oxygen treatment (HBO) offers one possibility
to increase the oxygen content in various tissues [7-10].
The use of HBO in cancer therapy has been aimed at
improving the radiation response in solid tumors [10] as
well as to improve healing of normal tissue after radiation
injury [11]. The increase in tissue pO2 during and after
HBO treatment is due to enhanced transport of soluble
oxygen. The physically solved oxygen at normobaric air
pressure is approximately 0.3 ml O2/l00 ml blood, with a
corresponding HbO2  of approximately 21 ml/100 ml
blood. By breathing 100% oxygen at normobaric pres-
sure, the amount of physically soluble oxygen increases 6
times (1.8 ml O2/100 ml blood). If the atmospheric pres-
sure is elevated to 3 bar in the presence of 100% O2, the
amount of oxygen delivered to the tissue would increase
to 6.0 ml O2/100 ml blood, which is even sufficient to
support resting tissue independent of the O2 contribution
from hemoglobin [12]. When oxygen is in solution, it can
reach physiologically obstructed areas that are inaccessi-
ble to the HbO2-containing red blood cells. In line with
this, several investigators have measured a significant
delay in washout (15–60 min) of the pO2 in different
tumors after HBO treatment [3,7-9].
Due to the apparent link between blood supply, oxygena-
tion and tissue growth, it has for a long time been a mis-
conception that HBO per se could have a tumor-
promoting effect. There are now several lines of evidence
showing that this is not the case [13]. In a rat model of
dimethyl-α-benz-anthracene (DMBA)-induced mammary
adenocarcinomas, we have recently demonstrated a sig-
nificant decrease in mammary tumor size after repeated
HBO treatment at 2 bar for 90 minutes [14]. These para-
doxical data indicate that an increase in the delivery of
physically dissolved O2 in the tumor tissue by hyperbaric
hyperoxic treatment may suppress its growth.
The present study was initiated to see if 1.5 bar (pO2 =
1.5) as well as pure oxygen at normal atmospheric pres-
sure (1 bar, pO2 = 1.0) would have a similar effect. The
aim of the present study was therefore to find the least
pressure gradient that gave a therapeutic effect on tumor
growth. Therapeutic efficacy was determined by assessing
tumor growth, angiogenesis, apoptosis, general morphol-
ogy and gene expression profiling.
Methods
Animal model of mammary tumors
Female Sprague-Dawley (Møllegård, Denmark) rats (n =
35) were used. Mammary tumors (adenocarcinomas)
were induced by dimethyl-α-benz-anthracene (DMBA)
dissolved in olive oil and given to the 7 week rat by gavage
at a dose of 16 mg. The experiments were performed when
the rats were 13–15 weeks old, having reached a body
weight of 250–300 g and developed tumors along the
mammary crest. Tumor size was measured externally by
calipers on day 1, 4, 7, and 11 and estimated according to
the following formula: π/6 · (a)2(b), where a is the short-
est transversal diameter and b is the longest transversal
diameter. The examinations were performed by the same
person, with no knowledge about the various exposures of
the rats. All measurements were performed during isoflu-
ran (Shering-Plough AS, Narum, Denmark) and N2O
anesthesia (Ohmeda: BOC Health Care, Weast-Yorkshire,
England). The study was approved by the Norwegian
Committee for Animal Research (Oslo, Norway).
Experimental groups and treatment design
Four separate groups of rats were studied (for details see
Table 1).
Table 1: The experimental groups.
Gas Total pressure (bar) pO2 (bar) Drug No. of rats
Group 1 Air 1.0 0.2 NaCl 10
Group 2 Air 1.0 0.2 5-FU 10
Group 3 Oxygen 1.0 1.0 NaCl 8
Group 4 Oxygen 1.5 1.5 NaCl 8
The hyperbaric oxygen treatement and 5-FU (0.2 mg/kg i.p.) were given on day 1, 4, 7 and 10.BMC Cancer 2007, 7:23 http://www.biomedcentral.com/1471-2407/7/23
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Hyperbaric chamber and oxygen exposure procedure
130 l hyperbaric chamber with an internal diameter of 50
cm was used. For inspection and video supervision there
are two windows in the chamber wall. Penetrators for gas
inlet and outlet run through the chamber's end wall. The
chamber and rat cage were cleaned and degreased (96–
100% ethanol) before starting exposure with pure oxygen.
All electrical installations were disconnected. The rats
were placed in litter-free cages (590 × 385 × 200 mm) dur-
ing HBO exposure. All rats were showered slightly with
water prior to entering the pressure chamber, due to the
danger of fire in a pure oxygen atmosphere. Four petrid-
ishes with water were placed on the chamber floor to
additionally humidify the atmosphere. To initiate the
treatment, 100% oxygen was introduced into the chamber
as air was simultaneously flushed out. The oxygen concen-
tration in the chamber was monitored continuously by an
oxygen cell (C3, Middelsborough, England). When oxy-
gen was above 98%, the rats of group 3 were kept at this
level for 90 min, while in group 4 the chamber was pres-
surized with oxygen over approximately 2 min to 1.5 bar,
and this pressure was maintained throughout 90 min.
During the 90 min period, the chamber was flushed twice
for 5 min (at 30 and 60 min) with pure oxygen in both
series. The temperature was held at approximately 22°C
and the humidity at approximately 100%. The CO2 con-
tent was kept low by use of a scrubber material (Sodasorb,
Molecular Products United Drug Co Ltd, Essex, UK)
placed inside the chamber floor.
Morphological analyses
The animals were sacrificed with pentobarbital during iso-
fluran and N2O anesthesia, and the tumors were dissected
out (one tumor from each rat). One part of the tumor was
fixed in 4% buffered formalin, processed and embedded
in paraffin. Tissue sections of each specimen were stained
using Harris Haematoxylin and Eosin (H & E, Merck,
Damstadt, Germany). The sections were analyzed with
regards to apoptosis (TUNEL assay) and blood vessel den-
sity (von Willebrand factor). Indirect immunohistochem-
istry was performed by the EnVisison™ + System, horse-
radish peroxidase and 3'3'-diaminobenzidine (DAB)
(DAKO, Glostrup, Denmark) method, as described in the
manufacturer's protocol.
TUNEL staining
Apoptosis was examined by the terminal transferase-
mediated dUTP nick end-labeling (TUNEL) method (Boe-
hringer Mannheim, Mannheim, Germany), performed
according to the manufacturers recommendations. The
DNA strand breaks in apoptotic cells are labelled by
attaching biotin-or digoxygenin conjugated dUTP in a
reaction catalyzed by exogenous terminal deoxynuclepti-
dyl transferase (TdT-assay) or DNA polymerase. For anti-
gen retrieval the slides were put into citrate buffer (0.1 M,
pH6.0) and then microwaved for 5 min. The slides were
washed in PBS before terminal deoxynucleotidyl trans-
ferase was applied to each slide and incubated for 1 hr at
37°C in a humidified chamber. A stop/washing buffer
was used before applying the converter POD (anti-fluores-
cein antibody conjugated with peroxidase as reporter
enzyme) for 30 min. Diaminobenzidine (DAB) was used
as a chromogen and the slides were counterstained with
hematoxylin. The density of apoptotic cells per mm2 of
the tumor viable zone was determined using a counter
grid (10 random vision fields × 40). The percentage of
apoptotic cells is expressed as a percentage of total cells.
Von Willebrand factor
For detection of vascular endothelial cells we stained for
Von Willebrand factor. The rabbit anti-human polyclonal
antibody against Von Willebrand factor (DAKO) was
diluted in TrisBSA to a 1:250 and than to a 1:500 dilution.
The tissue sections were incubated for 45 min and 75 min
respectively with the primary antibody, washed three
times for 5 min in TBS and further incubated with anti-
rabbit IgG (DAKO Cytomation Envision Kit, Labelled Pol-
ymer – HRP Anti Rabbit) for 35 min. All incubations were
performed in a humidity chamber. The tissue was then
washed three times with PBS. Detection was carried out
using a DAB chromogen, which resulted in a positive
brown staining. Harris Haematoxylin (Merck, Damstadt,
Germany) was used for nuclear counterstaining. Negative
control slides were obtained by omitting the primary anti-
body. Quantification of the microvessels was performed
in 10 consecutive fields in both the center and in the
periphery and averaged as vessels/mm2. Approximately
50 blood vessels in both the periphery and central part of
the tumor were randomly selected for diameter measure-
ments.
All the specimens were examined in a Nikon light micro-
scopy (THP Eclipse E600, Nikon Corporation, Tokyo,
Japan) and the images captured with a Nikon Digital
Camera (DXM 1200F, Nikon Corporation, Tokyo, Japan).
The image processing and analysis system LUCIA, version
4.8 (Laboratory Imaging Ltd, Prague, The Check Republic)
was used.
RNA extraction and microarray-based expression analysis
Specimens of tumor tissue (approximately 2 × 1 × 0.3 cm)
were immersed in ice cold RNA-later solution (Ambion,
Foster City, CA), and kept at 4°C over night. On the fol-
lowing day, the tissue tubes were frozen at -20°C until
RNA isolation. The tumor tissue samples were homoge-
nised by a Kinematica Polytron homogenizer. Total RNA
was extracted using the QIAGEN RNAeasy Lipid kit, and
the amount and quality of the extracted RNA was meas-
ured by the NanoDrop® ND-1000 Spectrophotometer andBMC Cancer 2007, 7:23 http://www.biomedcentral.com/1471-2407/7/23
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the Agilent 2100 Bioanalyzer. Purified total RNA was
stored at -80°C until use.
Twenty microgram total RNA was reversely transcribed
and fluorescently labelled using the Agilent Fluorescent
Direct Label Kit (G2557A), according to the manufac-
turer's instructions. To screen for gene expression changes
in mammary tumors as a result of hyperoxic exposure,
competitive hybridisations of samples from the treated
tumors (Group 3, 100% O2, 1 bar) against the untreated
tumors (normal air, 1 bar) were performed, where four
hyperoxia-treated tumor samples were each compared to
a pool of ten control tumors. Test samples were labelled
with Cy5 and control samples labelled with Cy3. After the
labelling reactions, the dye-incorporation ratio was deter-
mined using a spectrophotometer, showing ratios within
10 to 20 pmol per µg cDNA. The amount of the Cy-
labelled cDNA was checked by measuring its optical den-
sity in the NanoDrop® ND-1000 Spectrophotometer, at
OD 260/280 nm for DNA purity and at OD 550 nm and
650 nm for dye incorporation. The amount of cDNA out-
put was 1–2 µg and the dye incorporation was about 5%
for Cy3 and 3% for Cy5.
All hybridisations were carried out on Agilent 22 k Rat
Oligo Microarrays (G4130A), with 22,575 60-mer probes
representing over 20,000 rat genes, ESTs and EST clusters.
For hybridisation, the Agilent 60-mer oligo microarray
processing protocol (V 4.1, SureHyb 22 k chamber/SSC
wash) was strictly followed. Briefly, the entire labelling
reactions for Cy3-labelled control samples and Cy5-
labelled test samples were combined and applied to the
microarray together with control targets and hybridisation
buffers provided by the Agilent in situ hybridization plus
kit (5184–3568). The microarrays were then incubated in
an Agilent hybridisation oven (G2545A) with rotation for
17 hours at 60°C. On the following day, microarrays were
washed and immediately dried using an ultra pure filtered
N2stream. All operations were in accordance with the
manufacturer's instructions.
After drying, the slides were scanned for fluorescence sig-
nals by the Agilent G2565AA Microarray Scanner with a
pixel size of 10 nm. The TIFF images generated by the
scanning process were imported into GenePixPro 5.0 soft-
ware (Axon Instruments Inc) for primary data analysis.
Control spots and spot artifacts were flagged in GenePix
for subsequent filtering and background-corrected signal
intensity values were imported into the J-Express Pro V2.6
software (MolMine, Bergen, Norway)[15]. Flagged spots
were filtered and the red versus green signal intensities of
each spot were adjusted by global normalization to reduce
the impact of dye bias in the data sets.
Identification of genes with significant differential expres-
sion in hyperoxic exposed tumors was carried out using
'significance analysis of microarrays' (SAM) (16). The nor-
malized dataset from J-Express was imported into the
TM4 Microarray Software Suite Multi Experiment Viewer
3.1 (MeV) (TIGR, US). Signal intensities in all HBO
treated 'test' samples were compared to those of the
untreated 'control' samples. The analysis threshold was set
to a highly conservative false discovery rate of zero.
Real-Time PCR Analysis
Total RNA was extracted, quality controlled and stored as
described above. From each of the samples, 50 ng RNA
was reverse transcribed to cDNA using TaqMan RT rea-
gents (Applied Biosystems, Foster City, CA). The final con-
centrations of the reagents were as follows: 1 × TaqMan RT
buffer, 5.5 mM MgCl2, 2 mM dNTP mixture, 2.5 mM ran-
dom hexamers, 0.4 U/µl RNase inhibitor and 1.25 U/µl
Multiscribe reverse transcriptase in RNase-free water to a
total volume of 50 µl. The reaction mix was incubated at
25°C for 10 min (primer annealing), 48°C for 30 min
(synthesis) and 95°C for 5 min (enzyme inactivation).
The resulting cDNA samples were stored at -20°C. All sub-
sequent real-time PCR experiments were performed on an
ABI Prism 7900 HT sequence detector system using 384-
well plates. The PCR reaction solution for parotid secretory
protein (Psp), prolactin induced protein (Pip) and common
salivary protein 1 (Csp1) contained 1 µl 20 × TaqMan Gene
Expression Assays (Applied Biosystems) and 10 µl 2 ×
TaqMan Universal PCR Master Mix. The acidic ribosomal
protein P0 (P0) reaction solution contained 10 µl 2 ×
SYBR green (Medprobe), together with forward and
reverse primers (Sigma-Aldrich) in a final concentration
of 300 nM. All PCR reactions contained 4 µl of cDNA reac-
tion mix and RNasefree water to a total volume of 20 µl.
The real-time PCR was run as follows: 50°C for 2 min
(UNG incubation) and 95°C for 10 min (AmpliTaq Gold
activation), followed by 40 cycles of 95°C for 10 s and
60°C for 1 min. For each sample, the gene expression was
quantified by the standard curve method and normalized
against the expression of the ribosomal protein P0 gene.
The standard curve consisted of five points that were
obtained by a two-fold serial dilution of control RNA,
starting out at 250 ng, together with a 'non-template' con-
trol; all performed in triplicate. P0 was preferred as the
endogenous control over GAPDH and b-actin, which
both gave qualitatively similar results in pilot experiments
(data not shown).
Statistics
Results were expressed as means ± SD unless indicated
otherwise. Differences between groups were assessed by
unpaired, two-tailed Student's t-test or the Mann-Whitney
U test. P < 0.05 was considered significant.BMC Cancer 2007, 7:23 http://www.biomedcentral.com/1471-2407/7/23
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Results
Tumor growth
A total of 36 tumors were studied (one from each rat). The
tumor size ranged from 1.2 to 2.3 cm3 prior to the start of
the experiments (Day1). The marked increase in tumor
size found in controls (group 1, n = 10) over a period of
11 days (p < 0.001), was reduced by administering 5-FU
to the animals (group 2, n = 10, p < 0.02). A further reduc-
tion in tumor size was observed at day 11 after both 1.0
bar (group 3, n = 8) and 1.5 bar (group 4, n = 8) hyperoxia
treatment as compared to controls (p < 0.01) and 5-FU
treated rats (p < 0.05). Our previous study at 2 bar, 100%
O2 significantly attenuated tumor growth in the same
tumor model (included in Fig. 1) [14]. Taken together
these results indicate a reduction in growth that is dose-
dependent on pO2.
Down-regulation of glandular secretory proteins
Since these results confirmed our previous findings that
hyperoxia might attenuate the growth of rat mammary
tumors, we decided to perform a global gene expression
profiling to search for differentially expressed genes and
their biological function. By comparison of global gene
expression level in 5 hyperoxia treated tumors with a pool
of 10 control tumors, we notably observed a small cluster
(n = 5) of genes involved in glandular secretion that were
all strongly down-regulated by the exposure of the tumors
to 100% O2 (Table 2). These proteins included parotid
secretory protein (Psp), common salivary protein 1 (Csp1) and
prolactin induced gene (Pip), cystein-rich secretory protein
(crisp-1) and proline rich proteoglycan 2 (Prpg2). All these
genes displayed moderate to high expression levels in the
control tumors, but after a total of 6 hours of hyperoxic
treatment their expression was dramatically diminished,
with a down-regulation ranging from 5–33 times in the
individual tumors. To verify the microarray results, we
used quantitative real- time PCR, which confirmed that
the expression of Psp, Pip and Csp1 was markedly dimin-
ished in the hyperoxia-exposed tumors (Table 2).
General morphology
The gene expression data indicated that HBO treatment
was associated with attenuation of glandular function in
the mammary tumor. Subsequently the E & H stained
tumor tissue sections, clearly demonstrates that normo-
baric and as well as hyperbaric hyperoxia treatment
induced large areas of empty space ("vacuoles") both in
the central parts (Fig 2A) and in the periphery (Fig 2B) of
the tumor tissue compared to control (Table 3), thereby
indicating a loss of glandular tissue. The morphology of 1
and 1.5 bar sections were identical.
Tumor vessels
In order to analyse the impact of hyperoxia on the induc-
tion of vessel formation, the vascular densities in "hot
spot" areas (areas of high vascular density) in both the
tumor centre and periphery were examined. The mean
vascular density was markedly reduced in the tumors
treated with hyperoxia compared to controls (Table 3).
The ratio of central/peripheral vessel density is given in
Table 3. The diameter of the remaining tumor vessels was,
however, increased after hyperoxic treatment compared to
control, as can be seen in Table 3. The results also show
that the diameter of the peripheral vessels is larger than in
the central parts in both control and at 1 bar hyperoxic
treatment. The ratio of central/peripheral vessel diameter
is given in Table 3. The relationship between tumor vol-
ume and mean vessel density is visualized in Fig 3.
Tumor cells
The percentage of apoptotic cells in TUNEL-stained tissue
section was significantly increased (18–21%) after hyper-
oxic treatment compared to controls as shown in Table 3.
Discussion
The present study shows that exposing rats to normobaric
(1 bar) or hyperbaric (1.5 bar) hyperoxia (100% O2), four
times for 90 minutes, over a period of 10 days signifi-
cantly retards tumor growth. In the present model this
treatment showed more efficacy than the commonly used
chemotherapeutic drug 5-FU. Hyperoxic treatment did
affect the mammary tumors by significantly down-regu-
lating glandular genes that may have implications in
tumor growth (loss of glands), reducing vascular density
and enhancing apoptosis.
HBO is not a tumor promoter
HBO has been used in combination with both chemo-
therapy and radiotherapy to enhance the pO2 in the oth-
erwise hypoxic tumor tissue and thereby potentiate the
effect of these treatments [10]. HBO has also been used for
wound healing, treatment of necrotic tissues and recovery
of radiation-injured tissues because of its ability to pro-
mote angiogenesis and thereby enhance blood supply to
the injured area [10,11]. However, it has for a long time
been a misconception that HBO per se could have a tumor
promoting effect. There are now several lines of evidence
showing that this is not the case [13]. The present work
support previous conclusions from our group demon-
strating that HBO has a significant inhibitory effect on
mammary tumor growth in rats [14]. Also two studies on
mice injected with various tumor cell lines exposed to
70% O2 for 3 weeks showed a reduced number of lung
colonies derived from mammary carcinoma MT-7 cells
and of lung-tumor cell lines [17,18]. Some cell lines have,
however been shown to be oxygen resistant [17], which
indicates differences in the oxygen sensitivity in different
tumor-types.BMC Cancer 2007, 7:23 http://www.biomedcentral.com/1471-2407/7/23
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The effect of normoxic and hyperoxic treatment on tumor growth compared to controls and 5-FU treated Figure 1
The effect of normoxic and hyperoxic treatment on tumor growth compared to controls and 5-FU treated. Treatments were 
given on day 1, 4, 7 and 10. Values represent means ± SE.
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Hyperoxia changes the morphology of the tumor by 
inducing loss of glands
In addition to the tumor growth retardation, the mor-
phology of heamatoxylin-eosin stained tumor tissue
showed significant changes after hyperoxic treatment.
Most pronounced were the empty spaces in the tumor tis-
sue, which suggests a loss of glands in the mammary tissue
as indicated by a strong turn-off of glandular secretory
proteins (parotid secretory protein, prolactin induced
protein and common salivary protein-1) (Table 2). One
of the glandular secretory proteins, prolactin, stimulates
tumor growth and motility of human breast cancer cells
and a recent review suggested that antagonizing prolactin
should be evaluated as a tumor treatment [19]. It is there-
fore very surprising that hyperoxic treatment alone could
down-regulate the prolactin induced protein and therby
most likely also prolactin.
Hyperoxia has an anti-angiogenic effect
Hypoxia induce the formation of new tumor blood ves-
sels necessary for further tumor growth [20]. One might
therefore expect that hyperoxia should prevent tumor ang-
iogenesis. Normally, hyperoxic treatment is known to
enhance angiogenesis in wound healing, in necrotic ulcers
and after radiation injury [10,11]. Surprisingly, the
present study demonstrates that hyperoxia reduce the
mean vessel density in mammary tumors. This indicates
that hyperoxia induce an anti-angiogenic effect in tumor
tissue which is opposite to what is expected in "normal"
tissues. Another, surprising finding was the increase in
vascular diameter both in the periphery and central parts
of the tumor, since HBO is generally know to induce vaso-
constriction. This vasodilatory effect might indicate that
the tumor is struggling to elevate its flow to compensate
for the loss of blood vessels and thereby prevent starva-
tion.
Many tumor models have demonstrated a close correla-
tion between local oxygen deficiency and the production
of HIF-1α and VEGF [21,22]. HIF-1α activity as well as
VEGF secretion is tightly regulated by the oxygen-level,
and in the well oxygenated state they are rapidly degraded
[24]. Thus by increasing the pO2 in tumor tissue with nor-
mobaric and hyperbaric oxygen it is reasonable to assume
Table 2: Hyperoxia-induced changes in expression of secretory proteins in DMBA-induced mammary tumors in rats
Gene Name Gene symbol Change in expression levela RefSeq Probe ID
Array Q-PCR
Parotid secretory protein Psp 3.0E-02 1.0E-04 NM_052808 A_43_P12746
Prolactin induced protein Pip 5.1E-02 6.0E-04 NM_022708 A_43_P12308
Cysteine-rich secretory protein 1 Crisp1 4.6E-02 ND NM_022859 A_42_P457387
Common salivary protein 1 Csp1 5.8E-02 7.1E-02 NM_133622 A_42_P562492
Proline-rich proteoglycan 2 Prpg2 2.2E-01 ND NM_172065 A_42_P765648
a) The fold change in expression level was determined as the ratio between HBO-treated- and control-tumors. Values correspond to fold decrease, 
i.e. down-regulation of expression. The data are means of ratios obtained from four HBO-treated tumors compared to a pool of control tumors. 
ND: Not determined.
Table 3: Area fraction of vacuoles, number of apoptotic cells, mean vascular density, vascular diameter and ratio central/peripheral 
vessel density and vessel diameter in controls and in tumors treated with hyperoxia. Values are given as means ± SD.
Control 1 bar, 21% O2 
pO2 = 0.21
Test 1 bar, 100% O2 
pO2 = 1.0
Test 1.5 bar, 100% O2 
pO2 = 1.5
Area fraction vacuoles "empty spaces" 0.01 ± 0.04 0.11 ± 0.05 *** 0.21 ± 0.02 ***
Apoptotic cells (% of total cells) 61% ± 6.4 85% ± 7.3 *** 88% ± 5.0 ***
Mean vascular density (number of vessels/mm2) 
Centrally 98 ± 18.6 50.1 ± 17.4*** 69.8 ± 18.5*
Periphery 79.5 ± 19.2 38.5 ± 19.3*** 51.8 ± 26.8*
Vascular diameter (µm) 
Centrally 19.1 ± 4.9 23.1 ± 9.1 ** 23.2 ± 10.1**
Periphery 10.9 ± 3.9†† 12.5 ± 4.7 *†† 23.9 ± 10.0 ***
Ratio central/peripheral vessel density 1.2 ± 0.7 1.6 ± 1.3 1.5 ± 1.1*
Ratio central/peripheral vessel diameter 1.9 ± 0.8 2.0 ± 1.2 1.1 ± 0.6***
*P < 0.05, **P < 0.01, ***P < 0.001 vs control (1 bar, air)
††P < 0.01 vs centrallyBMC Cancer 2007, 7:23 http://www.biomedcentral.com/1471-2407/7/23
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Examples of eosin-hematoxylin stained tumor-tissue of the central (A) and peripheral (B) part of the mammary tumor in con- trol (left) and during hyperoxic treatment (right, 1 bar, pO2 = 1.0) Figure 2
Examples of eosin-hematoxylin stained tumor-tissue of the central (A) and peripheral (B) part of the mammary tumor in con-
trol (left) and during hyperoxic treatment (right, 1 bar, pO2 = 1.0). The images under A are scaled to the same magnification (× 
4) and the images under B to the same magnification (× 10). Scale bar indicate 500 µm (A) and 100 µm (B).BMC Cancer 2007, 7:23 http://www.biomedcentral.com/1471-2407/7/23
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that VEGF and HIF-1α would have been down-regulated.
The anti-angiogenic effect found in the present study
would correspond to this hypothesis.
Hyperoxia induces apoptosis
We found the amount of normal cells (cells with intact
nucleus) in the tumor to be decreased after hyperoxic
treatment. It is therefore important to know that hyper-
oxic treatment in the present range (1 -1.5 bar, pO2= 1–
1.5) and time exposed (90 min) have never been shown
to induce cell death of other tissues of the body, including
lungs which are known to be most susceptible to HBO
(UHMS) [25]. A review by O'Reilly stated that cell prolif-
eration (of normal tissue) in adult rats, mice and monkeys
exposed to lethal levels of oxygen (>90%) was unaffected
for the first 48, and alveolar epithelium relative unaffected
until after 72 hours [26]. However, a recent report [27] on
in vitro benign and malignant mammary epithelial cells
showed that HBO (97.9% oxygen) at a high pressure (2.4
bar) inhibited epithelial cell proliferation. Furthermore,
an organised, genetically programmed cell death was
found in the tumor tissue after hyperoxic treatment as
indicated by elevated amount of tunnel-positive apop-
totic cells.
Potential mechanism?
We might speculate that all or at least some of the changes
we have mentioned after both normobaric and hyperbaric
hyperoxia are due to free oxygen radicals (ROS). ROS
activity is known to be elevated during hyperoxia [28,29].
When level of free oxygen radical production exceeds
endogenous cellular antioxidant capacity it can create an
"oxidative stress" which can lead to cell death [30]. Free
oxygen radicals have previously been shown to induce
apoptosis and also inhibit angiogenesis [31]. In the litera-
ture it seems as if ROS has "two faces". It appears as
though the action of free radicals on normal and tumor
cells are opposite. When free radicals attack normal cells,
DNA damage can occur, whereas ROS in tumor cells has
an unexpected, but highly beneficial action, namely inhi-
bition of tumor cells [review:31]. Since the supoxide dis-
mutase (SOD) activity in most tumors has been shown to
be lower than in normal tissue, this might make the
tumors even more susceptible to increased ROS activity
during hyperoxic exposure. So, a moderate increase in
ROS activity by HBO might be beneficial in tumors.
Conclusion
The present study shows that both normobaric (1 bar,
pO2 = 1.0) and hyperbaric hyperoxia (1.5 bar, pO2= 1.5)
significantly retards mammary tumor growth in rats.
Hyperoxic treatment did affect the mammary tumors by
inducing loss of glands, reducing vascular density and
enhancing apoptosis. The mechanisms behind these
changes are still not known. Hyperbaric oxygen treatment
should therefore be further evaluated as adjuvant tumor
treatment.
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The relationship between tumor size and blood vessels per  mm2 before and after hyperoxic treatment Figure 3
The relationship between tumor size and blood vessels per 
mm2 before and after hyperoxic treatment. Values repre-
sents mean ± SE.
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